Posted by Michael Wonder on 31 Mar 2021
FDA approves Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
31 March 2021 - While the median progression free survival for Sarclisa combination therapy is not yet reached, consistent improvement in progression-free survival is seen across patient sub-groups.
The U.S. FDA has approved Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.
